The impact of minimally invasive surgery on hospital readmissions, emergency department visits and functional recovery after distal pancreatectomy

Risk factors of delayed gastric emptying after distal pancreatectomy: A comprehensive systematic review and meta-analysis

BACKGROUND

Delayed gastric emptying (DGE) is a common complication after distal pancreatectomy (DP). However, its incidence and risk factors remain unclear. This meta-analysis aims to clarify the incidence and risk factors associated with DGE following DP.

METHODS

We conducted a systematic search of PubMed, EMBASE, Web of Science, and the Cochrane Library for studies on DGE after DP, covering publications up to July 4, 2024. Odds ratios (OR) and 95 % confidence intervals (95 %CI) were pooled using random-effects or fixed-effects models. And heterogeneity testing and bias assessment were conducted.

RESULTS

A total of 82 studies involving 35,248 patients were included. The pooled analysis showed an incidence of DGE after DP of approximately 5.0 %. Among seven non-surgical risk factors, benign lesions as a protective factor for DGE after DP,while age over 75 was identified as potential risk factor for DGE after DP. Of the 21 surgical-related risk factors, early drain removal and laparoscopic distal pancreatectomy (LDP) were linked to a lower incidence of DGE, while factors such as hemorrhage, multivisceral resection, postoperative pancreatic fistula (POPF), portal vein resection, postoperative abscess, and wound infection were identified as potential risk factors for DGE after DP.

CONCLUSION

The incidence of DGE after DP is approximately 5.0 %. Risk factors include malignancy, open distal pancreatectomy (ODP), delayed drain removal, age over 75, hemorrhage, multivisceral resection, POPF, portal vein resection, postoperative abscess, and wound infection. This meta-analysis provides valuable insights for clinical practice, especially in improving the screening and management of high-risk patients. However, further large-scale, multicenter randomized controlled trials are needed to confirm these findings.

Minimally invasive versus open distal pancreatectomy for pancreatic Tumors: An updated meta-analysis and meta-regression

This study aims to compare the efficacy and safety of minimally invasive distal pancreatectomy (MIDP) and open distal pancreatectomy (ODP) for pancreatic neoplasms. A meta-analysis following PRISMA guidelines, registered on PROSPERO, included randomized controlled trials (RCTs) and propensity-score matched studies. Data from Cochrane Central, PubMed, and Embase were analyzed, focusing on procedure efficacy (e.g., length of hospital stay and reoperations), oncologic outcomes (e.g., R0 resections), surgical outcomes (e.g., blood loss and operative time), and postoperative outcomes (e.g., 90-day mortality, severe complications, pancreatic fistula). Among 23 studies, MIDP showed significantly reduced 90-day mortality (OR: 0.57, p = 0.03), severe (CDC ≥ III) complications (OR: 0.81, p = 0.04), hospital stay (MD: 2.38 days, p < 0.01), reoperations (OR: 0.65, p < 0.01) and blood loss (MD: 137.66 mL, p < 0.01) compared to ODP. No significant differences were found in postoperative pancreatic fistula (OR: 1.06, p = 0.74) or operative time (MD: 1.95 min, p = 0.87). ODP showed a significantly lower incidence of R0 resections (OR: 1.57, p < 0.01). Subgroup analyses of RCTs favored MIDP for 90-day mortality, severe complications, and hospital stay, but found no differences in pancreatic fistula or operative time. Meta-regression identified age and tumor size as influential covariates. MIDP offers superior outcomes in procedure efficacy, surgical and postoperative outcomes compared to ODP. These findings highlight MIDP as a safe and effective alternative for pancreatic surgery, supported by robust subgroup and sensitivity analyses.

The Implications of Readmission on Cost and Patient Outcomes Following Distal Pancreatectomy and Splenectomy

BACKGROUND

Robotic platform usage for distal pancreatectomy and splenectomy has grown exponentially in recent years. This study aims to identify the impact of readmission following robotic distal pancreatectomy and splenectomy and to analyze the financial implications of these readmissions.

METHODS

We prospectively followed 137 patients after robotic distal pancreatectomy and splenectomy. Readmission was defined as rehospitalization within 30 days post-discharge. Total cost incorporated initial and readmission hospital costs, when applicable. Outcomes were analyzed using chi-square/Fisher's exact test and Student's t test. Data are presented as median (mean ± SD).

RESULTS

Of 137 patients, 20 (14%) were readmitted. Readmitted patients were 67 (66 ± 10.3) years old and had a BMI of 30 (30 ± 7.0) kg/m2; 9 (45%) had previous abdominal operations. Non-readmitted patients were 67 (62 ± 14.7) years old and had a BMI of 28 (28 ± 5.7) kg/m2; 37 (32%) had previous abdominal operations (P = NS, for all). Readmitted patients vs non-readmitted patients had operative durations of 327 (363 ± 179.1) vs 251 (293 ± 176.4) minutes (P = .10), estimated blood loss (EBL) of 90 (159 ± 214.6) vs 100 (244 ± 559.4) mL (P = .50), and tumor diameter of 3 (4 ± 2.0) vs 3 (4 ± 2.9) cm (P = 1.00). Initial length of stay (LOS) for readmitted patients vs patients who were not readmitted was 5 (5 ± 2.7) vs 4 (5 ± 3.0) days (P = 1.00); total hospital cost of those readmitted, including both admissions, was $29,095 (32,324 ± 20,227.38) vs $24,663 (25,075 ± 10,786.45) (P = .018) for those not readmitted.

DISCUSSION

Despite a similar perioperative course, readmissions were associated with increased costs. We propose thorough consideration before readmission and increased patient education initiatives will reduce readmissions after robotic distal pancreatectomy and splenectomy.

Early biochemical predictors of clinically relevant pancreatic fistula after distal pancreatectomy: a role for serum amylase and C-reactive protein

BACKGROUND

Recent evidence suggests that pancreatic inflammation plays a pivotal role in the occurrence of clinically relevant postoperative pancreatic fistula (CR-POPF) after pancreaticoduodenectomy but few data are available for distal pancreatectomy (DP). The aim of this study was to evaluate the impact of early biochemical markers on the occurrence of CR-POPF after DP.

METHODS

Clinical and laboratory data for 432 consecutive DP patients were reviewed. Serum amylase was evaluated on postoperative day (POD) 1, and drain fluid amylase (DFA) and C-reactive protein (CRP) were evaluated on POD 2 and 3. Receiver operator characteristic (ROC) curves were performed for all biochemical markers and an area under the curve (AUC) was computed. Multivariable regression analyses to identify the factors associated with CR-POPF and severe postoperative morbidity (Clavien-Dindo grade ≥ 3) were performed.

RESULTS

At 90 days after surgery, CR-POPF occurred in 155 (36%) patients, severe complications in 66 (15%) patients. ROC curve analyses showed that DFA on POD2 had the largest AUC (0.753, p < 0.001), followed by serum amylase on POD 1 (0.651, p < 0.001), serum CRP on POD3 (0.644, p < 0.001), and CRP change between POD 2 and POD 3 (0.644, p < 0.001). Multivariable analysis identified male gender (OR 2.29, 95% CI 1.36-3.86; p = 0.002), DFA ≥ 1500 U/L on POD2 (OR 4.63, 95% CI 2.72-7.89; p < 0.001), serum amylase ≥ 100 U/L on POD 1 (OR 1.72, 95% CI 1.01-2.93; p = 0.046), and CRP increase by at least 25 mg/L on POD 3 compared to the previous day (OR 1.89, 95% CI 1.11-3.21; p = 0.019) as independent predictors of CR-POPF, yielding a valid regression model (AUC 0.765, 95% CI 0.714-0.816, p < 0.001).

CONCLUSIONS

Postoperative serum amylase and CRP trajectory represent useful early biochemical markers for CR-POPF in addition to DFA. Our findings suggest that these laboratory tests should be incorporated into clinical practice to aid postoperative patient and drain management.

Emergency Department Utilization Following Hepatopancreatic Surgery Among Medicare Beneficiaries

BACKGROUND

Care delivered in hospital-based emergency departments (ED) is a target for cost savings. ED utilization following hepatopancreatic surgery remains poorly defined. We sought to define the rate of ED utilization following liver and pancreatic resection, as well as to identify factors associated with ED visits post-discharge.

METHODS

The Medicare 100% Standard Analytic Files were used to identify Medicare beneficiaries who underwent hepatectomy or pancreatectomy between 2013 and 2017. Claims associated with ED services were identified using the relevant Revenue Center Codes. Patient characteristics and postoperative outcomes associated with ED care within 30 days of discharge were investigated.

RESULTS

Among 37,707 patients who underwent hepatopancreatic surgery, 10,323 (27.4%) had at least one ED visit within 30 days of discharge. Patients presenting to the ED were more likely to be male (OR 1.13, 95%CI 1.07-1.18). Patients undergoing a pancreatectomy (OR 1.39, 95%CI 1.32-1.47), as well as patients who had a perioperative complication (OR 1.16, 95%CI 1.10-1.23) and patients not discharged home (OR 1.41, 95%CI 1.33-1.49), were more likely to require ED care. In contrast, patients undergoing resection for cancer or surgery for an elective basis were less likely to present to the ED postoperatively (OR 0.92, 95%CI 0.87-0.97 and OR 0.22, 95%CI 0.20-0.23, respectively). Patients often had multiple ED visits within 30 days of discharge as 37.2% of patients presented to the ED with at least 2 visits. Visits were also most common in the immediate postoperative period, with 30.9% of ED visits taking place in the first 2 days from discharge. Among patients requiring postoperative ED care, 53.9% were readmitted within 30 days.

CONCLUSION

More than 1 in 4 patients undergoing hepatopancreatic surgery presented to the ED within 30 days of discharge, with most patients returning to the ED within the first week of discharge. A subset of patients had multiple ED visits. Future efforts should target patients most likely to be high ED utilizers to avoid the need for early post-discharge ED use.

Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach

Several studies showed safety and feasibility of laparoscopic distal pancreatectomy (LDP) as compared to open distal pancreatectomy (ODP). Patients who underwent LDP or ODP (2015-2019) were included. A 1:1 propensity score matching (PSM) was used to reduce the effect of treatment selection bias. Aim of this study was to identify those factors influencing the loss of benefit (defined as a significantly better outcome compared to ODP) after LDP. Overall, 387 patients underwent DP (n = 250 LDP, n = 137 ODP). After PSM, 274 patients (n = 137 LDP, n = 137 ODP) were selected. LDP was associated with reduced intraoperative blood loss (median: 200 mL vs. 250 mL, p < 0.001), decreased wound infection rate (1% vs. 9%, p = 0.044) and shorter time to functional recovery (TFR) (median: 4 days vs. 5 days, p = 0.002). Consequently, TFR > 5 days and blood loss > 250 mL were defined as loss of benefit after LDP. In the LDP group, age > 70 years [Odds Ratio (OR) 2.744, p = 0.022] and duration of surgery > 208 min (OR 2.957, p = 0.019) were predictors of TFR > 5 days and intraoperative blood loss > 250 mL, respectively. No differences in terms of TFR were found between ODP and LDP groups in patients > 70 years (p = 0.102). Intraoperative blood loss was significantly higher in the ODP group, also when the analysis was limited to surgical procedures with operative time > 208 min (p = 0.003). In conclusion, LDP seems comparable to ODP in terms of TFR in patients aged > 70 years. This finding could be helpful in the choice of the best surgical approach in elderly patients undergoing potentially challenging DPs.

Laparoscopic versus open distal pancreatectomy: a single centre propensity score matching analysis

The laparoscopic approach is considered as standard practice in patients with body-tail pancreatic neoplasms. However, only a few randomized controlled trials (RCTs) and propensity score matching (PSM) studies have been performed. Thus, additional studies are needed to obtain more robust evidence. This is a single-centre propensity score-matched study including patients who underwent laparoscopic (LDP) and open distal pancreatectomy (ODP) with splenectomy for pancreatic neoplasms. Demographic, intra, postoperative and oncological data were collected. The primary endpoint was the length of hospital stay. The secondary endpoints included the assessment of the operative findings, postoperative outcomes, oncological outcomes (only in the subset of patients with pancreatic ductal adenocarcinoma-PDAC) and total costs. In total, 205 patients were analysed: 105 (51.2%) undergoing an open approach and 100 (48.8%) a laparoscopic approach. After PSM, two well-balanced groups of 75 patients were analysed and showed a shorter length of hospital stay (P = 0.001), a lower blood loss (P = 0.032), a reduced rate of postoperative morbidity (P < 0.001) and decreased total costs (P = 0.050) after LDP with respect to ODP. Regarding the subset of patients with PDAC, 22 patients were analysed: they showed a significant shorter length of hospital stay (P = 0.050) and a reduction in postoperative morbidity (P < 0.001) after LDP with respect to ODP. Oncological outcomes were similar. LDP showed lower hospital stay and postoperative morbidity rate than ODP both in the entire population and in patients affected by PDAC. Total costs were reduced only in the entire population. Oncological outcomes were comparable in PDAC patients.